The open index of psychedelic research

Symptom-Specific Nuances in Psychedelic Integration: A Qualitative Study of Insights from Therapists Supporting Extended Difficulties in Naturalistic Settings

Wright A, Luke D, Robinson OC +1

PsiConnect: Multimodal Neuroimaging of Context-Dependent Brain and Behaviour Dynamics under Psilocybin.

Novelli L, Stoliker D, Barta T +7

Innovations in Depression Diagnosis and Treatment: A Review of Biological, Cognitive, and Psychosocial Advances.

Lyu G, Li D

How we're using AI tools to improve psychedelic-drug research.

Berghaus R

Change of substance-related hospitalisation in adolescents after cannabis legalisation in Thailand in 2022.

Puetpaiboon S, Rajborirug S, Nakhonsri V +5

Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.

Beichmann K, Catzeflis P, Aicher HD +4

MMP-1 Safety and efficacy of MDMA-assisted therapy for Post-Traumatic Stress Disorder in Military Veterans and First Responders: a randomised waitlist-controlled clinical trial

Cost-Effectiveness of Psilocybin-Assisted Therapy (PAT) for Patients with Treatment-Resistant Depression

MDMA-Assisted Therapy Randomized Controlled Trial Incremental Effects Systematic Review and Meta-Analysis

Borgogna NC, Whittington DD, Owen T +6

When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities.

Mitchell J, Bregman B, Surujnarain R +2

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality

Wießner I, Falchi-Carvalho M, Laborde S +7

Association of multimodal analgesic protocol with postpartum depression incidence and sleep quality in high-risk parturients.

Zhang H, Jiang YA, Fu H +2

Treatment-emergent psychiatric adverse events in patient-reported outcomes during ketamine use for major depressive disorder: a retrospective analysis.

Kwaśny A, Wilkowska A, Pastuszak M +2

Oral Ketamine for Depression: A Structured Evidence Table of Dosing Regimens, Clinical Outcomes, and Adverse Events

Alvear, Michael

361 Effect of intravenous psilocybin on mechanical hypersensitivity in a rat model of reserpine-induced chronic centralized pain

Huels E, Smith S, Liu T +1

265 Self-reported rates of psilocybin use in North Florida, 2012 to present

Millay T, Kodali M, Cottler L

ANESTHETIC CHALLENGE IN A PATIENT WITH COMPRESSIVE CERVICAL CHORDOMA: A CASE REPORT

Hassan Kraitiss , Yasser Ouatab , Marouane Jidal , Reda Amahroq , Youssef Halhoul , Aziz Benakrout and Mustapha Bensghir

Beyond the reducing valve: towards a computational neurophenomenology of altered states via deep neural networks.

Suzuki K

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.

Plourde L, Chang SL, Nguyen O +5

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

Tucciarone JM, Bandeira ID, Blasey C +13

Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study".

The Brinzei MDMA-PTSD Protocol: Addressing the Food and Drug Administration’s Breaking Blind Concerns with Precision Approaches to Post-Traumatic Stress Disorder Treatment

Brinzei OV

Safety and efficacy of esketamine versus remifentanil as adjuncts to propofol sedation in children undergoing haematologic-oncologic procedures in China: a single-centre, randomised, controlled, crossover trial protocol.

Xu S, Yang YF, Gao JM +5